Cargando…
A Review of MAL-PDT for the Treatment Strategy of Actinic Keratosis: Broader Clinical Perspectives Beyond the Data and Guideline Recommendations
Methyl aminolevulinate (MAL) is a topical compound approved for use with photodynamic therapy (PDT) for the treatment of actinic keratosis (AK) and field cancerization in certain countries. There exists a high burden of disease for patients with AK: repeated treatments are required, there is a known...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307748/ https://www.ncbi.nlm.nih.gov/pubmed/37300793 http://dx.doi.org/10.1007/s13555-023-00936-w |
_version_ | 1785066101462269952 |
---|---|
author | Szeimies, Rolf-Markus Dirschka, Thomas Fargnoli, Maria Concetta Gilaberte, Yolanda Hædersdal, Merete Chavda, Rajeev Calzavara-Pinton, Piergiacomo |
author_facet | Szeimies, Rolf-Markus Dirschka, Thomas Fargnoli, Maria Concetta Gilaberte, Yolanda Hædersdal, Merete Chavda, Rajeev Calzavara-Pinton, Piergiacomo |
author_sort | Szeimies, Rolf-Markus |
collection | PubMed |
description | Methyl aminolevulinate (MAL) is a topical compound approved for use with photodynamic therapy (PDT) for the treatment of actinic keratosis (AK) and field cancerization in certain countries. There exists a high burden of disease for patients with AK: repeated treatments are required, there is a known risk of progression to keratinocyte carcinoma, and cosmetic appearance is affected. Delivery of PDT using MAL is a flexible treatment strategy available in many forms; red light, daylight, or artificial daylight can be used for illumination, all of which result in high AK clearance rates and low recurrence. MAL-PDT protocols continue to evolve to further improve adherence and treatment outcomes. Here, we used PubMed to search MEDLINE to identify guidelines, consensus recommendations, and studies describing the use of MAL for the treatment of AK. The aim of this targeted review is to consider various MAL-PDT treatment strategies on the basis of published literature, with a focus on personalizing treatment for the heterogeneous AK population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13555-023-00936-w. |
format | Online Article Text |
id | pubmed-10307748 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-103077482023-06-30 A Review of MAL-PDT for the Treatment Strategy of Actinic Keratosis: Broader Clinical Perspectives Beyond the Data and Guideline Recommendations Szeimies, Rolf-Markus Dirschka, Thomas Fargnoli, Maria Concetta Gilaberte, Yolanda Hædersdal, Merete Chavda, Rajeev Calzavara-Pinton, Piergiacomo Dermatol Ther (Heidelb) Review Methyl aminolevulinate (MAL) is a topical compound approved for use with photodynamic therapy (PDT) for the treatment of actinic keratosis (AK) and field cancerization in certain countries. There exists a high burden of disease for patients with AK: repeated treatments are required, there is a known risk of progression to keratinocyte carcinoma, and cosmetic appearance is affected. Delivery of PDT using MAL is a flexible treatment strategy available in many forms; red light, daylight, or artificial daylight can be used for illumination, all of which result in high AK clearance rates and low recurrence. MAL-PDT protocols continue to evolve to further improve adherence and treatment outcomes. Here, we used PubMed to search MEDLINE to identify guidelines, consensus recommendations, and studies describing the use of MAL for the treatment of AK. The aim of this targeted review is to consider various MAL-PDT treatment strategies on the basis of published literature, with a focus on personalizing treatment for the heterogeneous AK population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13555-023-00936-w. Springer Healthcare 2023-06-10 /pmc/articles/PMC10307748/ /pubmed/37300793 http://dx.doi.org/10.1007/s13555-023-00936-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Szeimies, Rolf-Markus Dirschka, Thomas Fargnoli, Maria Concetta Gilaberte, Yolanda Hædersdal, Merete Chavda, Rajeev Calzavara-Pinton, Piergiacomo A Review of MAL-PDT for the Treatment Strategy of Actinic Keratosis: Broader Clinical Perspectives Beyond the Data and Guideline Recommendations |
title | A Review of MAL-PDT for the Treatment Strategy of Actinic Keratosis: Broader Clinical Perspectives Beyond the Data and Guideline Recommendations |
title_full | A Review of MAL-PDT for the Treatment Strategy of Actinic Keratosis: Broader Clinical Perspectives Beyond the Data and Guideline Recommendations |
title_fullStr | A Review of MAL-PDT for the Treatment Strategy of Actinic Keratosis: Broader Clinical Perspectives Beyond the Data and Guideline Recommendations |
title_full_unstemmed | A Review of MAL-PDT for the Treatment Strategy of Actinic Keratosis: Broader Clinical Perspectives Beyond the Data and Guideline Recommendations |
title_short | A Review of MAL-PDT for the Treatment Strategy of Actinic Keratosis: Broader Clinical Perspectives Beyond the Data and Guideline Recommendations |
title_sort | review of mal-pdt for the treatment strategy of actinic keratosis: broader clinical perspectives beyond the data and guideline recommendations |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307748/ https://www.ncbi.nlm.nih.gov/pubmed/37300793 http://dx.doi.org/10.1007/s13555-023-00936-w |
work_keys_str_mv | AT szeimiesrolfmarkus areviewofmalpdtforthetreatmentstrategyofactinickeratosisbroaderclinicalperspectivesbeyondthedataandguidelinerecommendations AT dirschkathomas areviewofmalpdtforthetreatmentstrategyofactinickeratosisbroaderclinicalperspectivesbeyondthedataandguidelinerecommendations AT fargnolimariaconcetta areviewofmalpdtforthetreatmentstrategyofactinickeratosisbroaderclinicalperspectivesbeyondthedataandguidelinerecommendations AT gilaberteyolanda areviewofmalpdtforthetreatmentstrategyofactinickeratosisbroaderclinicalperspectivesbeyondthedataandguidelinerecommendations AT hædersdalmerete areviewofmalpdtforthetreatmentstrategyofactinickeratosisbroaderclinicalperspectivesbeyondthedataandguidelinerecommendations AT chavdarajeev areviewofmalpdtforthetreatmentstrategyofactinickeratosisbroaderclinicalperspectivesbeyondthedataandguidelinerecommendations AT calzavarapintonpiergiacomo areviewofmalpdtforthetreatmentstrategyofactinickeratosisbroaderclinicalperspectivesbeyondthedataandguidelinerecommendations AT szeimiesrolfmarkus reviewofmalpdtforthetreatmentstrategyofactinickeratosisbroaderclinicalperspectivesbeyondthedataandguidelinerecommendations AT dirschkathomas reviewofmalpdtforthetreatmentstrategyofactinickeratosisbroaderclinicalperspectivesbeyondthedataandguidelinerecommendations AT fargnolimariaconcetta reviewofmalpdtforthetreatmentstrategyofactinickeratosisbroaderclinicalperspectivesbeyondthedataandguidelinerecommendations AT gilaberteyolanda reviewofmalpdtforthetreatmentstrategyofactinickeratosisbroaderclinicalperspectivesbeyondthedataandguidelinerecommendations AT hædersdalmerete reviewofmalpdtforthetreatmentstrategyofactinickeratosisbroaderclinicalperspectivesbeyondthedataandguidelinerecommendations AT chavdarajeev reviewofmalpdtforthetreatmentstrategyofactinickeratosisbroaderclinicalperspectivesbeyondthedataandguidelinerecommendations AT calzavarapintonpiergiacomo reviewofmalpdtforthetreatmentstrategyofactinickeratosisbroaderclinicalperspectivesbeyondthedataandguidelinerecommendations |